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Background: Ampicillin-resistant S. aureus (ARSA) now poses a serious problem for hospitalized patients, and their
care providers. Plant-derived antibacterial that can reverse the resistance to well-tried agents which have lost their
original effectiveness are the research objectives of far reaching importance. To this aim, the present study
investigated antibacterial and synergistic activities of Stephania suberosa extracts (SSE) against ARSA when
used singly and in combination with ampicillin.
Results: The majority chemical compounds of SSE were alkaloid (526.27 ± 47.27 mg/1 g of dried extract). The
Minimum inhibitory concentration (MICs) for ampicillin and SSE against all ARSA strains were >512 μg/ml and
4 mg/ml, respectively. Checkerboard assay revealed synergistic activity in the combination of ampicillin (0.15 μg/ml)
and SSE (2 mg/ml) at fractional inhibitory concentration index (FICI) <0.5. The killing curve assay had confirmed that
the viability of ARSA was dramatically reduced from 5x105 cfu/ml to 103 cfu/ml within 6 h after exposure to SSE
(2 mg/ml) plus ampicillin (0.15 μg/ml) combination. Electron microscopic study clearly revealed that these ARSA
cells treated with this combination caused marked morphological damage, peptidoglycan and cytoplasmic
membrane damage, and average cell areas significant smaller than control. Obviously, Immunofluorescence staining
and confocal microscopic images confirmed that the peptidoglycan of these cells were undoubtedly disrupted by
this combination. Furthermore, the CM permeability of ARSA was also increased by this combination. Enzyme assay
demonstrated that SSE had an inhibitory activity against β-lactamase in concentrations manner.
Conclusions: So, these findings provide evidence that SSE has the high potential to reverse bacterial resistance to
originate traditional drug susceptibility of it and may relate to three modes of actions of SSE: (1) inhibits
peptidoglycan synthesis, resulting in morphological damage, (2) inhibits β-lactamases activity, and (3) increases
CM permeability. It is widely recognized that many types of drugs are derived from alkaloids. So, this SSE offers
the prominent potential to develop a novel adjunct phytopharmaceutical to ampicillin for the treatment of ARSA.
Further active ingredients study, toxicity of it, and the synergistic effect on blood and tissue should be performed
and confirmed in an animal test or in humans.
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Since Alexander Fleming discovered the first antibiotic,
an increased emergence of multidrug resistance in
pathogenic bacteria has been globally documented. In
London, 38% of Staphylococcus aureus strains were re-
sistant to penicillin and increased to approximately 90%
in the UK and USA in the recent year [1]. Similarly, 70-
80% of S. aureus strains in most of Asian countries were
resistant to methicillin [2]. S. aureus infections are no-
torious etiological pathogens for several human ailments,
including pneumonia, meningitis, toxic shock syndrome,
bacteremia, wound sepsis, osteomyelitis, and endocardi-
tis [3-5]. This strain is also the second most common
cause of bloodstream infection with case fatality rates of
approximately 15-25% [6]. Methicillin-resistant S. aure-
us (MRSA) is notably one of the greatest threats to hu-
man health, and is the major causes of both hospital and
community-acquired MRSA infection that affects both
hospitalized patients and their health care providers
[7,8]. Methicillin, like ampicillin, is the one member of
penicillins. So, the resistance pattern of S. aureus against
both drugs are almost the same [9]. β-lactam antibiotics
are the most common and effective agents for treating
staphylococcal infections, but current higher resistance
levels were reported in these strains. A raised incidence
of β-lactam resistance in MRSA has rapidly emerged
due to mediated by acquisition of mecA encoded an
additional penicillin-binding protein 2a (PBP2a) result-
ing in reducing the ability of β-lactam in binding to its
target site. In summation, the production of blaZ
encoded β-lactamase that can hydrolyze and inactivate
β-lactam antibiotic activity, in particular penicillins.
This enzyme is also one of the most important resistant
mechanisms to β-lactam in this strain [10-12]. For these
problems, searching and development of novel antibac-
terial compounds or new strategies are urgently re-
quired. Plants are well known and being interested
sources for new antibacterial agents because they pro-
duce an enormous variety compounds to protect them-
selves from plant pathogens and environmental
pathogens [13]. Thus, plant-derived antibacterials are
often a source of novel therapeutics, but they have
weaker antibacterial activity compared to that of anti-
biotic generated by bacteria or fungi. Therefore, it
should be considered to use in a different paradigm, in-
cluding combination with conventional antibiotic that
has been resisted by bacteria to achieve synergism in
treatment of bacterial infections [14].
Phytochemical and antibiotic combination approach
has been recommended and tested by several reports for
combating multidrug-resistant bacteria by achieving
multiply synergistic drug targets, interacting with drug-
resistant mechanisms of bacteria, and neutralizing and
eliminating adverse effects [15-18]. Previous researchfound that the hasubanalactam alkaloid (glabradine) iso-
lated from Stephania glabra showed antimicrobial activity
against Staphylococcus aureus, S. mutans, Microsporum
gypseum, M. canis and Trichophyton rubrum greater than
those of novobiocin and erythromycin with IZD values of
19–27 cm [19]. To develop novel plant-derived antibacte-
rials, the Stephania suberosa was selected to investigate its
antibacterial property. S. suberosa belongs to Genus Ste-
phania and family Menisperamaceae. Plants in this genus
have been traditionally used for treatments of asthma, tu-
berculosis, dysentery, hyperglycemia, cancer, fever, intes-
tinal discomforts, sleep disturbances and inflammation.
Also, previous research found that the chemical com-
pounds in this plant were alkaloids such as, (+)-Cephar-
anthine and its derivative, stephasubimine and etc. [20].
Recently, however, limited study is available on antibac-
terial activity of S. suberosa. Hence, the purpose of this
investigation was to test the antibacterial activity and
synergism with ampicillin of this plant against ARSA.
Some elementary mechanism of actions, such as cy-
toplasmic membrane (CM) permeabilization, enzyme
assay, and transmission electron microscopy, was also
studied.Methods
Plant preparation and extraction
Roots of S. suberosa were purchased from Lamtakhong
Research Station, NakhonRatchasima Province, Thailand.
The plant specimens were deposited at the Thailand Na-
tional Herbarium and authenticated in comparison with
the voucher specimen no. BK257189 by Dr. Paul J. Grote,
a lecturer and plant biologist at Institute of Science,
Suranaree University of Technology, Thailand. The roots
of S. suberosa were cleaned thoroughly and dried under a
hot air oven at the 50°C until dry. The dried samples were
powdered using a grinder. Then, dried powder was ex-
tracted with 95% ethanol using Soxhlet extractor at 75°C
for 8 h. The extracts were concentrated using a rotary
evaporator and were lyophilized to yield a brown powder
and a dark brown sticky oil of ethanolic extract.
Preliminary qualitative phytochemical screening ana-
lysis was proceeded for notable bioactive compounds,
such as alkaloids, tannin, flavonoids, saponins, glyco-
sides, steroids, terpeniods, coumarins and anthocyanin.
The methods were achieved in accordance with previous
description and slightly modifications [21-24]. Screening
for the presence of the total alkaloid content in the ex-
tract was also accordingly carried out with previously re-
ported [25]. In brief, 1 g of the dried extract was
alkalinized with NH4OH, partitioned with chloroform,
and evaporated to dryness on a water bath at 60°C. The
net mass of triplicate remaining solid was accurately
weighed and expressed as milligrams per 1 g of dried
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by 95% ethanol and confirmed in the presence of
alkaloids.
Bacterial strains, antibiotics, chemicals, and antibodies
Clinical isolates of ampicillin-resistant S. aureus (ARSA)
DMST 20651, 20652 and 20653 were obtained from the
Department of Medical Science, National Institute of
Health, Ministry of Public Health, Thailand. The refer-
ence strain of S. aureus ATCC 29213 was obtained from
the American Type Culture Collection (ATCC). Ampi-
cillin, o-nitrophenol-β-D-galactoside (ONPG), nisin,
NH4OH, chloroform and β-lactamase type IV from En-
terobacter cloacae were obtained from Sigma-Aldrich,
UK. Mueller-Hinton broth was purchased from Oxoid
(Basingstoke, UK). Primary mouse monoclonal anti-
S. aureus peptidoglycan antibody (ab20002), secondary
goat polyclonal anti-mouse IgG conjugated with Alexa
Fluor®488 (ab150117), and fluoroshield mounting medium
with DAPI (ab104139) were purchased from Abcam, UK.
Bacterial suspension standard curve
In order to obtain a known viable count of bacterial sus-
pension, the method of Liu and company was followed
as previously described with some modifications [26].
Mueller-Hinton agar and Cation-adjusted Mueller-Hinton
broth (CAMHB) were practiced as a culture medium [27].
Minimum inhibitory concentration (MIC) determinations
MIC determinations of ampicillin, nisin, and SSE against
ARSA strains were performed following the method of
Liu et al. [26]; Eumkeb et al. [28] and Clinical and La-
boratory Standards Institute [27]. Briefly, bacterial sus-
pension was adjusted to approximately 1 × 108 cfu/ml
and serial tenfold dilution was performed to achieve 5 ×
106 cfu/ml. The diluted inoculum (0.1 ml) of each stain
was added to 0.9 ml of CAMHB plus serial dilutions of
the antibacterial agents, to give a final concentration ap-
proximately 5 × 105 cfu/ml. Antibiotics used and SSE
was prepared by dissolving in sterile distilled water to
obtain stock solutions at 1024 μg/ml for antibiotics or
1024 mg/ml of the extract. Then, the stock was serially
twofold diluted to achieve respective concentration. The
lowest concentration that showed no visible growth after
incubated at 35°C for 18 h was recorded as the MIC. S.
aureus ATCC 29213 was used as a reference strain.
Checkerboard determination
The interaction between SSE and ampicillin against
ARSA was assayed using checkerboard determination
following Eumkeb et al. [28] and Bonapace et al. [29].
Briefly, the cultured and antibacterial agents were pre-
pared and performed similarly with MIC determination.
Otherwise, the SSE and ampicillin were combined andincubated at 35°C for 18 h. The MICs were determined
as the lowest concentration SSE in combination with
ampicillin. The FIC index (FICI) was calculated to deter-
mine drug interaction, and interpreted as follows:
FIC index ¼ FICA þ FICB ¼ Conc: of A in MICs of Aþ BMIC of A alone
þ Conc: of B in MICs of Aþ B
MIC of B alone
Where, FICI ≤ 0.5 denoting synergistic; FICI > 0.5–4.0
denoting no interaction; FICI > 4.0 denoting antagon-
ism [30].
Killing curve determination
Killing curve determination was carried out in order to
confirm antibacterial and synergistic activities of SSE
when used singly and in combination with ampicillin.
The viabilities of drug resistant bacteria after exposure
to these agents alone and in combination at nine distinct
times (0, 0.5, 1, 2, 3, 4, 5, 6 and 24 h) were counted. The
assay was followed the previously described with some
modifications [28,31]. Concisely, inocula (5 × 105 cfu/ml)
were exposed to SSE either singly or in combination
with ampicillin. Aliquots (0.1 ml) of each exposed time
were removed and diluted in normal saline as needed to
enumerate 30–300 colonies. The diluted cultures were
platted and spread thoroughly on plates containing
MHA. After incubating at 35°C for 18 h, the growing
colonies were counted. The lowest detectable limit for
counting is 103 cfu/ml. The experiment was performed
in triplicate; data are shown as mean ± SEM.
The preliminary mechanism of action was performed
in duplicate methods for confirmation except for enzyme
assay that clearly determine by one method.
Transmission electron microscopy (TEM)
Ultrastructure damages of ARSA treated with SSE either
alone or in combination with ampicillin were examined
using TEM. TEM preparations were performed in ac-
cordance with previously reported with slight modifica-
tions [32]. After preincubated at 35°C for 18 h, ARSA
strains were adjusted spectrophotometrically to give a
final concentration approximately 5 × 105 cfu/ml. The
cultured were grown in the absence of antibacterial
agent (control), in SSE alone, ampicillin alone, and SSE
plus ampicillin combination, for 4 h with shaking 110
oscillations/min in a water bath at 37°C. Then, the cul-
tured were harvested by centrifugation at 6000 ×g for
15 min at 4°C and the pellets were fixed in 2.5% glutaral-
dehyde (Electron Microscope Sciences; EMS) in 0.1 M
phosphate buffer (pH 7.2) for 12 h. The samples were
then carefully washed twice with 0.1 M phosphate buf-
fer. Post-fixation was carried out with 1% osmium tet-
roxide (EMS) in 0.1 M phosphate buffer (pH 7.2) for 2 h
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samples were gently dehydrated with graded ethanol
(20%, 40%, 60%, 80% and 100%, respectively) for 15 min.
Then, infiltration and embedding were performed using
Spurr’s resin (EMS). The samples were sectioned using
an ultramicrotome with a diamond knife and were then
mounted on copper grids. Ultimately, the ultrathin sec-
tioned were counterstained with 2% (w/v) uranyl acetate
for 3 min and then 0.25% (w/v) lead citrate for 2 min.
After staining, the specimens were viewed in a Tecnai G2
electron microscope (FEI, USA), operating at 120 kV.
In addition, the cell area of these cells from micrographs
were calculated by measuring cell width multiplied by cell
length (nm2) in order to confirm the effects of SEE either
used singly and in combination on cell size.Immunofluorescence staining and confocal microscopy
Disruption of peptidoglycan after exposure to SSE either
used singly or in adjunction with ampicillin was carried
out by the immunofluorescence and visualized under a
confocal laser scanning microscope. The 18 h cultured
of ARSA was challenged with distinct agents; ampicillin
(256 μg/ml), SSE (2 mg/ml), ampicillin (0.11 μg/ml) plus
SEE (1.5 mg/ml) for 4 h. The cell grown without anti-
bacterial agent was used as a control. After incubation,
the cells were harvested by centrifugation and subse-
quently fixed with 2.6% paraformaldehyde and 0.04%
glutaraldehyde mixture for 10 min at room temperature,
and 50 min on ice. Fixed cells were washed and resus-
pended in PBS, smeared directly to poly-L-lysine coated
slides, and air-dried. Nonspecific antibody binding in the
samples was blocked with 5% BSA for 30 min at room
temperature. The specimens were consecutively incubated
with the primary antibody (1:800 dilution with PBS con-
taining 2% BSA), a mouse anti-S. aureus peptidoglycan
antibody, in a moist chamber for 1 h. The cells were
washed thoroughly with PBS containing 0.1% Tween 20.
The secondary antibody (Alexa 488-conjugated goat anti-
mouse IgG) was prepared by diluting with PBS plus 2%
BSA solution (1:1000) and incubated with the samples for
1 h in the dark at room temperature, several washed with
PBS + 0.1% Tween 20. To reduce photobleaching and to
counterstain bacterial DNA, the slides were mounted
with a few drops of fluoroshield mounting medium con-
taining 4′,6-Diamidino-2-Phenylindole (DAPI) [33]. Im-
ages were captured and performed with a confocal laser
scanning microscope (Nikon 90i A1R) equipped with
100x NA 1.40 oil objective (Nikon), Intensilight fiber il-
luminator (Nikon) and NIS Elements 4.11 AR/BR B871
(Nikon). DAPI and Alexa 488 were excited at 360 nm
and 488 nm, respectively. The background cell fluores-
cence was subtracted. An Adobe Photoshop CS5 was
used for the figure preparation.Cytoplasmic membrane (CM) permeability
SSE used either singly or in combination with ampicillin
induced CM permeability were examined by the ability
of these antimicrobial agents to disclose cytoplasmic β-
galactosidase activity in bacteria using ONPG as a sub-
strate. ONPG can be cleaved by β-galactosidase localized
within the cytoplasm. The products of β-galactosidase-
ONPG reaction were galactose (colorless) and o-nitro-
phenol (yellow). The assays were prepared in according
to the methods of Marri et al. and Eumkeb et al. with
slight modification [34,35]. Shortly, 18 h ARSA cultured
was adjusted to 5x105 cfu/ml and grown in CAMHB
without antibacterial agents (control), 2 mg/ml SSE,
256 μg/ml ampicillin and 1.5 mg/ml SSE plus 0.11 μg/ml
ampicillin in 110 oscillations/min in shaking water bath
at 37°C. These bacterial cells were then compiled to
analyze cytoplasmic membrane alteration at six different
interval times (0, 1, 2, 3, 4 and 5 h). Nisin (8 μg/ml) was
applied as a positive command. Each sample 2 ml ali-
quots at each time were transferred to tubes containing
ONPG (4 mg/ml) plus Phosphate buffered saline (PBS).
Observed yellow was recorded as positive β-galactosidase
activity (increased CM permeability), while appearing col-
orless was recorded as negative β-galactosidase activity
(no effect on CM permeability).
Apart from this, the second cytoplasmic membrane
permeabilization experiment was executed to confirm as
previously described by Shen et al. [36] and Zhou et al.
[37] with some modifications. This method was per-
formed by measurement the release of UV-absorbing ma-
terial concentrations using UV–VIS spectrophotometer.
In brief, the ARSA cultures were prepared on CAMHB
for 18 h at 35°C. Inocula of 2.0 ml of culture were added
into 98.0 ml CAMHB and shaking at 100 r.p.m. at 37°C
for 4 h to give log phase. Bacterial cultures were adjusted
in saline to give 5 x 106 cfu/ml. Log phase of the adjusted
cultures 1.0 ml was added to 9.0 ml of 2.5 mmol/l sodium
HEPES buffer (pH 7.0) supplemented with 100 mmol/l
glucose plus 256 μg/ml ampicillin, 2 mg/ml SSE (½ MICs),
and 0.11 μg/ml ampicillin plus 1.5 mg/ml SSE (¾ FIC) in
each flask to give a final concentration at 5 × 105 cfu/ml.
The flasks of cell suspensions without antibacterial
agent were used as the negative control and with 8
(μg/ml) nisin (½ MIC) was applied as positive control.
The bacterial suspensions were incubated at 37°C in the
shaker water bath. CM permeability was determined
after a contact time of 0, 0.5, 1.0, 2.0, 3.0 and 4.0 h. After
treatment, samples (1.0 ml) were taken every contact
time and filtered through a sterile nitrate cellulose
membrane (0.22 μm), and OD260 value of the super-
natant was taken as a percentage of the extracellular
UV-absorbing materials released by cells. All the mea-
surements were done in triplicates in Varian Cary 1E
UV/VIS spectrophotometer [28].
Teethaisong et al. Journal of Biomedical Science 2014, 21:90 Page 5 of 11
http://www.jbiomedsci.com/content/21/1/90Enzyme assay
The ability of SSE when used alone to deteriorate β-
lactamase type IV activity of E. cloacae was performed fol-
lowing the method as previously described by Richards
et al. [32] with little modifications. Concisely, benzylpeni-
cillin, a substrate for β-lactamase type IV, was adjusted to
concentrations sufficient to hydrolyze 50-60% substrate
within 5 min. SSE at 1, 2, and 4 mg/ml were preincubated
with enzyme in 50 mM sodium phosphate buffer (pH 7.0)
at 37°C for 5 min prior to adding a substrate. Time-course
assay were performed in 0, 5, 10, 15 and 20 min using
methanol/acetic acid (100:1) as a stopping agent. 10 μl
of each sample was injected to reverse-phase HPLC to
analyze the remaining benzylpenicillin. A mobile phase
employed was 10 mM ammonium acetate (pH 4.5 acetic
acid): acetronitrile (75:25) with flow rate 1 ml/min, UV
detector at 200 nm, Ascentis C18 column, and 35°C for
column temperature [9]. The quantity of remaining
benzylpenicillin was calculated by comparing the area
under the chromatographic curve.Statistical analysis of experimental data
All experiments were carried out in triplicate; data were
expressed as mean ± standard error of the mean (SEM)
due to it takes into account sample size. Significant dif-
ferences of cell area in each treated group from TEM,
CM permeability and enzyme assay among each treated
group at the same interval times were analyzed by one-
way ANOVA. A p valve <0.01 of Tukey’s HSD post-hoc
test was considered as statistically significant difference.Results
Phytochemical screening, MIC, and checkerboard
determinations
The preliminary phytochemical characteristics results of
SSE indicated that the presence of alkaloids, tannins, gly-
cosides, steroids, and anthocyanin were detected. The
total alkaloid containing in the extract was 526.27 ±
47.27 mg/1 g of dried extract. The MIC results of SSE,
ampicillin, and nisin against ARSA were 4 mg/ml, >512 μg/
ml, and 16 μg/ml respectively, while these agents against
susceptible S. aureus strain was 4 mg/ml, 0.25 μg/ml, and
0.5 μg/ml respectively (Table 1). According to CLSI, these
outcomes suggested that ARSA used in this study revealed
high resistant to ampicillin and nisin, but susceptible to ref-
erence strain S. aureus ATCC 29213. SSE exhibited little
inhibitory effect against these strains. In checkerboard
assay, based upon FICI calculation, the combination of SSE
and ampicillin exhibited synergistic activity at FICI <0.5
(Table 1). Obviously, the concentration of ampicillin that
can inhibit ARSA growth had considerably reduced from
>512 μg/ml to 0.15 μg/ml in combination with SSE.Killing curve determinations
The viable counts for ARSA after exposure to antimicro-
bial agents at different times are shown in Figure 1. The
control cells revealed no reduction in viable counts and
steady growth in log phase viable counts throughout
24 h. Whereas, no significant change was observed in
cells treated with the SSE and ampicillin alone. Interest-
ingly, the combination of the SSE plus ampicillin exhib-
ited a steady reduction of 5 × 105 cfu/ml to 103 cfu/ml
within 6 h and did not recover within 24 h. These results
had also been confirmed antibacterial and synergistic ac-
tivity of MIC and checkerboard determinations.TEM
The electron microscope images were chosen to present
from triplicate samples in each group. Electron micro-
scopic investigation clearly exhibited that the cytoplas-
mic membrane and cell wall of ARSA grown in the
absence of antibacterial agent (control) can be undoubt-
edly distinguished and no damage to ultrastructure was
observed (Figure 2a). ARSA treated with ampicillin
256 μg/ml alone showed slight peptidoglycan damage to
a minority of these cells (Figure 2b). A number of these
cells treated with SSE 2 mg/ml caused somewhat pep-
tidoglycan damage (Figure 2c). Besides, these average
cell areas were somewhat smaller than the control and
ampicillin groups, but not a significant difference (p >
0.01) (Figure 3). These findings indicate that the SSE
treated cells cause rather higher peptidoglycan damage
than ampicillin treated cells. Obviously, the synergistic
effect was observed with the combination of ampicillin
plus SSE that these cells demonstrated a lot of these
cells exhibited marked morphological damage, notice-
able peptidoglycan damage (Figure 2d). Obviously, these
average cell areas were significantly smaller than control
and others (p < 0.01) (Figure 3).Immunofluorescence staining and confocal microscopy
Confocal laser scanning images of peptidoglycan-labeled
ARSA unambiguously revealed intact coccus-shaped and
no damage was observed in control cell (Figure 4). Cells
treated with ampicillin and SSE alone showed a slight
damage to peptidoglycan, but SSE alone seemed to have
more damage than ampicillin alone. Substantial peptido-
glycan disruption was seen in cell received ampicillin
plus SSE combination. The bright field image of this
treated bacterium demonstrated distortion in cell shape
(a white arrow). Data from this experiment had ratified
damage of ARSA’s peptidoglycan after treatment with
SSE in adjacent with ampicillin. These results support a
predominant mechanism of action of this combination
probably be inhibiting peptidoglycan synthesis.
Table 1 MICs and FICI of SSE, AMP when used either alone or in combination against ARSA
Strains MIC FIC FIC index
AMP (μg/ml) SSE (mg/ml) NIS (μg/ml) AMP + SSE (μg/ml +mg/ml)
S. aureus DMST 20651 >512R 4.0ND 16 0.15 + 2.0 <0.5
S. aureus DMST 20652 >512R 4.0ND 16 0.15 + 2.0 <0.5
S. aureus DMST 20653 >512R 4.0ND 16 0.15 + 2.0 <0.5
*S. aureus ATCC 29213 0.25S 4.0ND 0.5 NT NT
S = Susceptible; R = resistant; ND = No data in CLSI; NT = not test; AMP = Ampicillin; SSE = S. suberosa crude extract; NIS = Nisin; FICI ≤ 0.5 denoting synergistic; FICI >
0.5–4.0 denoting no interaction; FICI > 4.0 denoting antagonism; *S. aureus ATCC 29213 was used as a reference strain.
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The effect of 256 μg/ml ampicillin, 2 mg/ml SSE alone
and the combination of 0.11 μg/ml ampicillin plus
1.5 mg/ml SSE on CM permeability determined by cyto-
plasmic β-galactosidase activity is illustrated in Table 2.
The result showed that there was no activity of β- galac-
tosidase with increasing time in cells grown without
antibacterial agent (control), with ampicillin and SSE
alone. Whereas, cell treated with SSE plus ampicillin
combination and nisin exhibited β-galactosidase activity
(observed yellow) after 1 h exposure time. These results
indicated that the combination of SSE plus ampicillin re-
vealed the ability to increase CM permeability of ARSA.
Furthermore, the cytoplasmic membrane permeability
was measured by UV-absorbing release materials as pre-
sented in Figure 5. After treatment ARSA cells with
8 μg/ml nisin, and 0.11 μg/ml ampicillin plus 1.5 mg/ml
SSE could induce the release of 260 nm absorbing ma-
terial, which we interpret to be mostly DNA, RNA,Time (h)




























Figure 1 Time killing-curve of ARSA after exposure to SSE,
ampicillin either alone or in combination. Con = control (drug
free); SSE (2) = SSE at 2 mg/ml; Amp(256) = ampicillin at 256 μg/ml;
SSE(2) + Amp(0.15) = SSE at 2 mg/ml plus ampicillin at 0.15 μg/ml;
the values plotted are the means of 4 observations, and the vertical
bars indicate the standard errors of the means.metabolites and ions significantly higher than controls,
ampicillin, and SSE alone within 0.5 h and throughout
the 4 h (p < 0.01). These results imply that the synergis-
tic activity of SSE plus ampicillin increased cytoplasmic
membrane permeability of this strain [36,37].
Enzyme assay
The ability of SSE to inhibit activity of β-lactamase type
IV isolated from E. cloacae was assayed by determining
the amount of remaining benzylpenicillin using reverse-
phase HPLC. As shown in Figure 6, the result displayed
that benzylpenicillin treated with SSE was significantly
higher than control starting from 5 minutes (p < 0.01).
The benzylpenicillin remainder was significantly increased
by an increase in SSE as a concentration-dependent man-
ner. These results suggest that one activity of SSE against
ARSA may involve in β-lactamase inhibition [9].
Discussion
The present investigation is the first report of antibacter-
ial and synergistic activities of S. suberosa extract when
used singly and in combination with ampicillin against
clinical isolated ARSA. The preliminary mechanisms of
action of those agents were also evaluated in this study.
Practically-prescribed antibiotic resistance in MRSA due
to drug target-site alteration, enzyme modification and
changes in membrane permeability, has increasingly
emerged. Therefore, the selection of antibiotic to treat
multidrug resistant MRSA has been daily decreasing. So,
the research approach to find out new anti-MRSA
agents are still necessary [4]. The MIC results revealed
that these testing S. aureus strains were highly resistant
to ampicillin alone because of the standard value of the
sensitivity of ampicillin against these strains are ≤
0.25 μg/ml [27]. As well as, SSE demonstrated little bac-
teriostatic effect against these strains while the reference
S. aureus strain exhibits susceptible to ampicillin. Like-
wise, these results are in substantial agreement with
those of Eumkeb et al. [9] that the MIC of ampicillin
against S. aureus DMST 20651 was > 1,000 μg/ml. Also,
the MIC result of nisin against MRSA strains seem con-
sistent with previous finding that 90% MIC of nisin
against MRSA was 16 μg/ml [38]. The checkerboard
Figure 2 Ultrathin sections of log phase of ARSA DMST 20651 grown in MHB: a = Control (bar = 500 nm, x19500; inset: bar = 100 nm,
x43000); b = 256 μg/ml ampicillin (bar = 500 nm, x15000; inset: bar = 200 nm, x38000); c = 2 mg/ml SSE (bar = 500 nm, x19500; inset:
bar = 200 nm, x38000); d = 1.5 mg/ml SSE plus 0.11 μg/ml ampicillin (bar = 500 nm, x8700; inset: bar = 200 nm, x29000).
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plus SSE against all of tested S. aureus strains with FIC
index at <0.50 [39]. These results are in substantial cor-
respondence with those of Eumkeb et al. that galangin,
quercetin or baicalein plus ampicillin exhibited synergis-
tic activity against penicillins-resistant S. aureus strains
at FIC indices < 0.03 [9]. Besides, previous studies re-
ported that a synergistic effect between quercetin and
oxacillin against vancomycin-intermediate S. aureus dis-
played the lowest FIC index value of 0.0417 [40]. Apart
from this, the antibacterial activity of quercetin plus
ampicillin or vancomycin against the sensitive MRSA
strain were significantly increased compared to control
(no any testing agent) (p < 0.01) [41]. As previously doc-
umented, drug combination approach by achieving a
synergistic effect can eliminate and neutralize the ad-
verse effects [16]. The killing curve determination can
confirm MIC and checkerboard determinations that syn-
ergistic effect of SSE plus ampicillin caused marked re-
duction in viable counts of ARSA cells from 6 h andthroughout 24 h. These results appear consistent with
previous findings that galangin, quercetin or baicalein
plus ceftazidime exhibited synergistic activity against
MRSA result in a large decrease from 6 to 24 h [9],
Apart from this, the combinations of baicalin and β-
lactam antibiotics showed that the killing of MRSA and
beta-lactam-resistant S. aureus cells were dramatic re-
duction by these combinations [26]. Clearly, the syner-
gistic effect of SSE plus ampicillin against ARSA was
observed. For this reason, the elementary mechanism of
action such as TEM, CM permeability, and enzyme assay
were more investigated.
TEM results of SSE plus ampicillin treated cells dem-
onstrated that ARSA cells exhibited marked morpho-
logical damage, clear peptidoglycan and cytoplasmic
membrane damage, and average cell areas significant
smaller than control. These results seem consistent with
previous findings that the combination of ceftazidime
plus galangin caused damage to the ultrastructures of



























Figure 3 The cell area of ARSA after treatment with SSE, ampicillin either alone or in combination: Con = control (drug free); Amp
(256) = ampicillin at 256 μg/ml; SSE (2) = SSE at 2 mg/ml; Am (0.11) + SSE (1.5) = ampicillin at 0.11 μg/ml plus SSE at 1.5 mg/ml; The
graph shows an area of cell determined by cell width x cell length (nm2). The different superscript alphabets are significantly different from
each other. Each treated group was compared using one-way ANOVA and Tukey’s HSD Post-hoc test, p < 0.01 are presented.
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http://www.jbiomedsci.com/content/21/1/90to an increase in cell size of ceftazidime-resistant S. aur-
eus [9]. The TEM results have been confirmed by con-
focal microscopic images that the peptidoglycan of this
combination treated cells was undoubtedly destroyed.
These effects can be explained by assuming that SSEFigure 4 Schematic representation of the results from immunofluores
ARSA after treatment for 4 h with Ampicillin, SSE, either alone or in c
suberosa extract at 2 mg/ml; Amp (0.1) + SSE (1.5) = Ampicillin 0.11 μg/ml p
and labeled for peptidoglycan (PGC) (green) using respective antibodies. D
a peptidoglycan layer (merged images). The white arrows showed explicitmay insert synergistic action with ampicillin to inhibit
peptidoglycan synthesis leads to marked morphological
damage and delay cell division.
The CM permeability revealed that SSE in combi-
nation with ampicillin increased cytoplasmic membranecence and a confocal laser scanning microscope; Samples of
ombination. Amp (256), ampicillin at 256 μg/ml; SSE (2), Stephania
lus SSE 1.5 mg/ml. The cells were stained for DNA with DAPI (blue)
NA in all groups was localized in the central of cell and surrounded by
disruption of peptidoglycan. Scale bar = 1 μm.
Table 2 β-galactosidase activity results of ARSA after treatment with ampicillin, SSE alone or in combination
Time Control (no drug) Amp (256) SSE (2) Amp + SSE (0.11 + 1.5) NIS (8) (positive control)
0 Neg Neg Neg Neg Neg
1 Neg Neg Neg Pos Pos
2 Neg Neg Neg Pos Pos
3 Neg Neg Neg Pos Pos
4 Neg Neg Neg Pos Pos
5 Neg Neg Neg Pos Pos
Neg, no evidence of activity; Pos, have evidence of activity; Amp (256), ampicillin at 256 μg/ml; SSE (2), Stephania suberosa extract at 2 mg/ml; Amp + SSE (0.11 +
1.5) = Ampicillin 0.11 μg/ml plus SSE 1.5 mg/ml; NIS (8), Nisin at 8 μg/ml was used as a positive control. The experiment was carried out in triplicate observations.
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http://www.jbiomedsci.com/content/21/1/90permeability of this strain. The β-galactosidase activity
result was virtually the same as UV-absorbing material
concentrations result that CM permeability was signifi-
cantly increased from 1 h onward (Table 2 and Figure 5).
These results are in substantial agreement with previous
findings that luteolin either alone or combined with
amoxicillin and apigenin alone and in combination with
ceftazidime increased CM permeability of amoxicillin-
resistant E. coli and ceftazidime-resistant E. cloacae re-
spectively [15,28]. In general, nisin incorporates into the
membrane and makes the membrane permeable for
ions. So that, both the membrane potential and pH gra-
dient are dissipated [42]. Apart from this, nisin inhibits
peptidoglycan synthesis and forms highly specific pores
through interaction with the membrane-bound cell wall
precursor lipid II [43]. The increase in CM permeability
may be one of the synergistic activity of this combinationTime (h)





































Figure 5 Presence of 260 nm absorbing material in the
supernatants ARSA treated with Ampicillin, SSE, either alone or
in combination. Amp (256), ampicillin at 256 μg/ml; SSE (2), Stephania
suberosa extract at 2 mg/ml; Amp (0.11 + 1.5) + SSE (1.5) = Ampicillin
0.11 μg/ml plus SSE 1.5 mg/ml; NIS (8), Nisin at 8 μg/ml was used as a
positive control and untreated cells were used as negative control. The
mean ± SEM for three replicates are illustrated. Means sharing the same
superscript are not significantly different from each other (Tukey’s
HSD, p < 0.01).against ARSA strain. The more SSE concentrations results
in more benzylpenicillin remainder of enzyme assay re-
sults are in substantial agreement with previous findings
that galangin inhibits β-lactamase in a concentration-
dependent manner [9]. Noteworthy that the SSE alone
could show β-lactamase inhibitory activity results in very
high MIC value. Whereas, its combination with ampicillin
showed a synergistic effect by peptidoglycan synthesis in-
hibition and increase CM permeability. Six new protober-
berines and ten known alkaloids were found in Stephama
suberosa root extracts [44]. However, the bioactive com-
pounds of S. suberosa extract that showed antibacterial ef-
fect in this study have not been well characterized.
Although, there is devoid of the report has been docu-
mented for toxicity of S. suberosa, but some plant in the
genus Stephania, for instance, previous studies found that
the LD50 of oral feeding of aqueous extract of Stephania
cepharantha wet and dry root tuber in mice were 41.4 g/
kg and 22.9 g/kg respectively [45]. In addition, the acute
toxicities of protoberberine alkaloids, berberine, coptisine,
palmatine and epiberberine, from Rhizoma coptidis (RC)Time (min)







































Figure 6 The inhibitory activity of SSE against β-lactamase type
IV from E. cloacae in hydrolyzing benzylpenicillin; Con = control
(no testing agent); SSE(1) = SSE at 1 mg/ml. The graph shows the
remaining benzylpenicillin at the same time. Means sharing the
same superscript are not significantly different from each other
(Tukey’s HSD, p < 0.01).
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http://www.jbiomedsci.com/content/21/1/90were evaluated, the LD50 value of four alkaloids were
713.57, 852.12, 1533.68 and 1360 mg/kg, respectively.
The sub-chronic toxicity study in rats treated with the
RC alkaloids at a dose of 156 mg/kg/day for 90 days
revealed that no abnormality in clinical signs, body
weights, organ weights, urinalysis, hematological pa-
rameters, gross necropsy, histopathology, no mortality
and morbidity were observed in any of the animals [46].
Likewise, the acute oral LD50 of lupanine from Lupinus
angustifolius in rats was 1464 mg/kg [47]. Our finding
found that the total alkaloid content in SSE was ap-
proximately 526.27 mg/1 g of dried extract. The FIC for
SSE in combination with ampicillin against ARSA was
2 mg/ml, possibly therefore the total alkaloids of
1.05 mg may roughly presented in 2 mg/ml. In this case,
the in vitro determination of starting dose for in vivo
tests was used to predict starting doses for subsequent
in vivo acute lethality assays. The results lend support
to the assumption that if most of these alkaloids are
Cepharanthine, the estimated LD50 was > 5,000 mg/kg,
which is classified as practically nontoxic [48,49].
Hence, SSE when used in combination with ampicillin
at this concentration may have a sufficient margin of
safety for therapeutic use. Obviously, many alkaloids
have been used as modern medicine, for example col-
chicine (anti-gout), quinine (anti-malaria), morphine
and codeine (analgesics), reserpine (anti-hypertension),
vinblastine and vincristine (anti-cancer), theophylline
(anti-asthma) [50,51]. However, further investigation
should be focused on active ingredients of SSE that play
an important role on antibacterial effect, as well as tox-
icity confirmation is still necessary.
Conclusions
In summary, our study provides evidence that SSE has
the extraordinary potential to reverse bacterial resistance
to originate traditional drug susceptibility of it. This is
the first report of the mechanism of synergistic action of
SSE plus ampicillin combination against ampicillin-
resistant S. aureus. Three modes of actions would be
implied that this combination inhibit peptidoglycan syn-
thesis, inhibit β-lactamases activity, and increase CM
permeability. So, this Stephania suberosa proposes the
high potential to develop a useful of novel adjunct phy-
topharmaceutical to ampicillin for the treatment of
ARSA. Future studies should be investigated and con-
firmed the efficacy and toxicity of this combination in an
animal test or in humans, Also, The synergistic effect on
blood and tissue would be evaluated and achieved.
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